Compare Abeona Therapeutics Inc (ABEO) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs KraneShares Hang Seng TECH Index ETF — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while KraneShares Hang Seng TECH Index ETF trades at $12.99. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | KTEC | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $19.51 |
52-Week Low | $4.17 | $12.00 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
KTEC trades at $12.51, up 0.89% with bearish technical signals from moving averages while oscillators remain neutral. The stock faces resistance at $13 and support at $12. Financial ratios including P/E, P/S, and ROE are unavailable in current data, limiting fundamental assessment. No recent company news or earnings updates are available for analysis.
The technical outlook appears cautious with bearish momentum indicators, though the stock shows short-term stability near current levels. Investment opportunity depends on forthcoming financial disclosures to evaluate valuation and growth prospects. Key risks include limited public financial data availability and potential volatility given the technical bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
